EP0324802A1 - Procede permettant de traiter des tissus osseux et de leur administrer des medicaments - Google Patents

Procede permettant de traiter des tissus osseux et de leur administrer des medicaments

Info

Publication number
EP0324802A1
EP0324802A1 EP88903116A EP88903116A EP0324802A1 EP 0324802 A1 EP0324802 A1 EP 0324802A1 EP 88903116 A EP88903116 A EP 88903116A EP 88903116 A EP88903116 A EP 88903116A EP 0324802 A1 EP0324802 A1 EP 0324802A1
Authority
EP
European Patent Office
Prior art keywords
oxygenated
perfluorocarbon
fluid
drugs
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88903116A
Other languages
German (de)
English (en)
Other versions
EP0324802A4 (en
Inventor
Edward S. Neiss
Charles G. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abeona Therapeutics Inc
Original Assignee
Chemex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemex Pharmaceuticals Inc filed Critical Chemex Pharmaceuticals Inc
Publication of EP0324802A1 publication Critical patent/EP0324802A1/fr
Publication of EP0324802A4 publication Critical patent/EP0324802A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the invention relates to a method for a treatment of and the administration of drugs to body tissues and surfaces.
  • this invention particularly relates to the treatment of structures such as the skin or mucosa which are in need of enhanced or supplemental oxygen supply.
  • This invention also relates to the treatment of individuals or tissues within individuals which may additionally or alternatively require the administration of drugs.
  • Yet another long sought goal of medical science is ' an effective, non-invasive technique for the percutaneous administration of drugs.
  • Most known methods are not well suited to be used by patents (e.g., intraveneous injection) or result in poor absorption and utilization of the drug (e.g., enceric administration). It is therefore an object of this invention to provide a method of treatment which will supplement or restore the-;; oxygen supply to damaged tissues. It is also an object of this invention to provide a method of treatment which facilitates the effective percutaneous administration of drugs which can be useful in the treatment of disease and especially useful in the treatment of damaged or diseased mucosa or skin.
  • damaged bodily tissue is treated by oxygenating a pharmaceutically acceptable liquid with a therapeutically effective amount of oxygen and then applying the oxygenated liquid to the affected tissue.
  • another therapeutic agent is dissolved or suspended in the liquid in addition to • or in place of oxygen.
  • This therapeutic agent may be selected from an exceptionally wide variety of drugs including antibiotics, anti-inflamatories or mixtures of such agents or drugs.
  • Another highly useful group of therapeutic agents are those which are useful in treating skin diseases such as acne, psoriasis, angina pectoris or skin cancers.
  • perfluorinated hydrocarbons are generally insoluble in water it is highly preferred that an aqueous emulsion of the perfluorinated hydrocarbons to be used.
  • Fluosol-DA Green Cross
  • Oxypherol-ET Alpha Therapeutic Corporation. The composition of Oxypherol-ET is set forth in Table II.
  • the Oxypheral-ET formulation may be modified by increasing the hydroxyethyl starch level to from 5- to 20%.
  • the oxygenation of the perfluorocarbon or perfluorocarbon emulsion used in the process of the present invention can be carried out by exposing the fluid to an atmosphere of at least 75% oxygen, although an atmosphere of at least 95% oxygen is preferred. This is most effectively accomplished by bubbling oxygen at slightly greater than atmqspheric pressure through the perfluorocarbon. Once oxygenated, the perfluorocarbon or perfluorocarbon emulsion may be applied directly to damaged tissue.
  • Perfluorocarbon preparations are known to be able to dissolve at least 40% of oxygen and it is desirable to use fully saturated preparations when treating oxygen starved tissues. However, even oxygen starved tissues benefit substantially from the use of 25% solutions.
  • the oxygenated fluid should be applied to the affected tissue at regular intervals to obtain maximum therapeutic effect. It is expected that it will be necessary to reapply the oxygenated fluid to the affected tissue 2 to 6 times each day.
  • topical or percutaneous administration of drugs can be accomplished with special advantage by the process of the present invention and the absorption of drugs is accomplished with suprising effectiveness.
  • the affected tissue has suffered injury as a result of a trama or where secondary infection is present or seriously possible, it will be advisable to include a therapeutic concentration of an appropriate antibotic in the oxygenated perfluorocarbon fluid.
  • Therapeutic concentrations of some suitable topical antibotics are set forth in Table III.
  • Polymyxin B 0.5-1.5% by wt.
  • an anti-inflamatory agent may be included in the oxygen-containing liquid which is used in the present invention.
  • an anti-inflamatory agent may be included in the oxygen-containing liquid which is used in the present invention.
  • hydrocortisone 0.5 to 1.5% by weight
  • Other therapeutic agents which may be used include nordihydroquaiaretic acid and its derivatives, the usefulness of which is described in co-pending United States Patent Application No. 699,923, filed February 2, 1985.
  • a wide variety of drugs can be administered with exceptional effectiveness through healthy skin by the process of the present invention. This process, therefore, has broad application in the percutaneous administration of drugs without regard to its usefulness as an oxygen supply technique.
  • a bedsore may be treated by applying to it sufficient volume of oxygenated Oxypherol-ET to completely over the sore.
  • the sore can be seen to begin to heal within 2 weeks and heal completely in about 4 weeks as the above described procedure is repeated every 12 hours.
  • nitroglycern can be dissolved in the above-mentioned perfluorocarbon composition and applied in a patch on the skin of a patient suffering from angina pectoris. This procedure can provide immediate and sustained relief to the patient.
  • Oxypherol-ET oxygenated Oxypherol-ET to completely over the sore.
  • the sore can be seen to begin to heal within 2 weeks and heal completely in about 4 weeks as the above described procedure is repeated every 12 hours.
  • nitroglycern can be dissolved in the above-mentioned perfluorocarbon composition and applied in a patch on the skin of a patient suffering from angina pectoris. This procedure can provide immediate and sustained relief to the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

On applique un fluide oxygéné aux tissus corporels abîmés, permettant ainsi aux tissus d'être oxygénés. On peut oxygéner et utiliser dans ce procédé des hydrocarbures perfluorés. Divers agents thérapeutiques peuvent être mélangés au fluide oxygéné et administrés aux tissus abîmés.
EP19880903116 1986-09-19 1987-08-18 Method for the treatment of body tissues and the administration of drugs thereto Withdrawn EP0324802A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90983286A 1986-09-19 1986-09-19
US909832 1986-09-19

Publications (2)

Publication Number Publication Date
EP0324802A1 true EP0324802A1 (fr) 1989-07-26
EP0324802A4 EP0324802A4 (en) 1991-07-24

Family

ID=25427897

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880903116 Withdrawn EP0324802A4 (en) 1986-09-19 1987-08-18 Method for the treatment of body tissues and the administration of drugs thereto

Country Status (4)

Country Link
EP (1) EP0324802A4 (fr)
JP (1) JPH01503146A (fr)
AU (1) AU2807689A (fr)
WO (1) WO1989000848A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847009A (en) * 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
US5284645A (en) * 1987-08-05 1994-02-08 Alliance Pharmaceutical Corp. Fluorocarbon emulsions containing amino acid based anti-inflamatory agents and buffer systems
US5061688A (en) * 1988-08-19 1991-10-29 Illinois Institute Of Technology Hemoglobin multiple emulsion
DE4100059C2 (de) * 1991-01-03 1994-08-25 Adatomed Pharma & Med Behandlungsflüssigkeit zum Wiederanlegen (Entfalten) abgelöster Netzhaut an die Aderhaut des Auges
US5200430A (en) * 1991-03-21 1993-04-06 Escalon Ophthalmics, Inc. Debridement of bodily cavities using debridement fluids
DE4221268C2 (de) * 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
US5643601A (en) * 1992-06-26 1997-07-01 Lancaster Group Ag Phospholipid-and fluorocarbon-containing cosmetic
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
DE4221256C2 (de) * 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
WO1994023748A1 (fr) * 1993-04-08 1994-10-27 The University Of Queensland Administration d'un agent vaso-actif et d'un agent therapeutique
GB9308280D0 (en) * 1993-04-21 1993-06-02 Stead Gordon Thickening of fluorinated liquids
US5470885A (en) * 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
EP0729359A4 (fr) * 1993-11-15 1999-06-02 Baker Med Res Inst Procede de traitement du dysfonctionnement cardiaque et compositions pharmaceutiques utilisables a cet effet
DE4405627A1 (de) * 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
CN102223877A (zh) * 2008-11-25 2011-10-19 奥斯金生医公司 全氟化碳凝胶

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE881267A (fr) * 1980-01-18 1980-05-16 Stein Karl N Methode pour le traitement de brulures de la peau chez les mammiferes
WO1981000002A1 (fr) * 1979-06-25 1981-01-08 Suntech Utilisation de carbone perfluore pour le traitement des brulures
EP0112658A2 (fr) * 1982-11-26 1984-07-04 Children's Hospital Medical Center Dispositif extraoculaire pour le traitement de l'oeil

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2743842C2 (de) * 1976-10-01 1982-07-01 Matsushita Electric Industrial Co., Ltd., Kadoma, Osaka Trockenelektrolytkondensator und Verfahren zu dessen Herstellung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981000002A1 (fr) * 1979-06-25 1981-01-08 Suntech Utilisation de carbone perfluore pour le traitement des brulures
BE881267A (fr) * 1980-01-18 1980-05-16 Stein Karl N Methode pour le traitement de brulures de la peau chez les mammiferes
EP0112658A2 (fr) * 1982-11-26 1984-07-04 Children's Hospital Medical Center Dispositif extraoculaire pour le traitement de l'oeil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8900848A1 *

Also Published As

Publication number Publication date
WO1989000848A1 (fr) 1989-02-09
EP0324802A4 (en) 1991-07-24
AU2807689A (en) 1989-03-01
JPH01503146A (ja) 1989-10-26

Similar Documents

Publication Publication Date Title
EP0324802A1 (fr) Procede permettant de traiter des tissus osseux et de leur administrer des medicaments
CN101287457B (zh) Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
EP0279379B1 (fr) Administration interstitielle d'emulsions de composés perfluorés pour la reoxygénation de cellules cancéreuses hypoxiques
Bell et al. Regional anesthesia with intravenous lidocaine
US4555524A (en) Transdermal 2-(4-isobutylphenyl)-propionic acid medication and methods
JPS60100517A (ja) 放射線潰瘍治療剤および方法
JP2002510618A (ja) 皮膚科症状の治療へのポリアミンの使用
DE68907081T2 (de) Mittel mit erhöhtem Penetrationsvermögen.
CA1302253C (fr) Utilisation de protoporphyrine stanneuse et de mesoporptyrine stanneuse dans le traitement du psoriasis
JP2004521112A (ja) 関節痛治療薬を製造することへの神経毒性物質の使用
WO1985005036A1 (fr) Traitement topique du diabete a l'aide d'insuline et d'un agent ameliorant la penetration applique sur la peau et recouvert d'une pastille
GARB et al. Mycosis fungoides with bullous lesions: report of a case resistant to roentgen and arsenical therapy; effects of empiric therapy, partly based on laboratory investigations
Glick et al. Phase I clinical trials of WR-2721 with alkylating agent chemotherapy
KR0145678B1 (ko) 트리글리세라이드를 함유하는 포도필로톡신 제제
JP2640597B2 (ja) 創傷治癒促進剤
CN114831939B (zh) 一种醋酸曲安奈德组合物喷雾剂及其制备方法
CN1177587C (zh) 利鲁唑和α-生育酚联合制剂
CN1748758A (zh) 血竭凝胶制剂及其制备方法
EP0137807A1 (fr) Composition antivirale et son procede d'administration
JPH06199672A (ja) 活性成分としてクロラムフェニコール、ゲンタマイシンおよびナイスタチンを含有する、炎症性皮膚疾患の局所治療のための配合製剤
Lund et al. AN EVALUTION of Epidural Analgesia in Geriatric Surgery
RU2442565C1 (ru) Лечебная мазь
EP1291039B1 (fr) Utilisation d'un mélange de lidocaine et prilocaine, et composition pour anesthésie locale tumescente
EP1507524A1 (fr) Utilisation de diur tiques pour traiter les oed mes
CA1066620A (fr) Melange de proteines extraites du foie et methode d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19880519

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NEISS, EDWARD S.

Inventor name: SMITH, CHARLES G.

A4 Supplementary search report drawn up and despatched

Effective date: 19910607

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19910823